Literature DB >> 26642711

Association of FOXP4 Gene with Prostate Cancer and the Cumulative Effects of rs4714476 and 8q24 in Chinese Men.

Ming Liu, Xiaohong Shi, Jianye Wang, Yong Xu, Dong Wei, Yaoguang Zhang, Kuo Yang, Xin Wang, Siying Liang, Xin Chen, Fan Yang, Liang Sun, Xiaoquan Zhu, Chengxiao Zhao, Ling Zhu, Lei Tang, Chenguang Zheng, Ze Yang.   

Abstract

BACKGROUND: The tumor suppressor forkhead box P4 (FOXP4) plays important roles in oncogenesis, and the FOXP4 variant rs1983891 is associated with prostate cancer (PCa) in several studies. However, association studies conducted in Northern and Southern Chinese have provided conflicting results. Therefore, here we performed fine mapping of FOXP4 to identify the association with PCa and the potential application in Chinese men.
METHODS: We examined 11 variants spaced approximately 55 kb apart spanning FOXP4 using high-resolution melting-curve analysis and sequencing methods in 286 PCa patients and 630 controls, and the association between these variants and PCa risk was evaluated. Additionally, we evaluated the cumulative effect of rs4714476 and 2 variants in 8q24 (rs16901966, rs10090154) confirmed in our previous study.
RESULTS: Of 11 SNPs, only rs4714476-C at the 5' near gene of FOXP4 was associated with increased age-adjusted PCa risk (p = 0.012, OR = 1.32, 95% CI = 1.06 - 1.63) and aggressive PCa (p = 0.026). The CG haplotype covering rs4714476-C demonstrated significant differences between PCa cases and controls (p = 0.009). The cumulative effect analysis showed men who carried any combination of 1, 2, or 3 risk genotypes had a gradually increased PCa risk (age-adjusted OR is from 1.244 to 3.312).
CONCLUSIONS: These data suggest that rs4714476 at the 5' near gene of FOXP4 potentially contributes to the susceptibility of PCa in Chinese men. The cumulative effect of rs4714476 at FOXP4 and 8q24 could increase PCa risk.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26642711     DOI: 10.7754/clin.lab.2015.150313

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  6 in total

1.  Evaluation of neutrophil-to-lymphocyte ratio as a prognostic indicator in a Singapore cohort of patients with clinically localized prostate cancer treated with prostatectomy.

Authors:  Yadong Lu; Hong Hong Huang; Weber Kam On Lau
Journal:  World J Urol       Date:  2019-04-05       Impact factor: 4.226

Review 2.  The functions, oncogenic roles, and clinical significance of circular RNAs in renal cell carcinoma.

Authors:  Hui Huang; Tao Chen; Fei Li; Dan Jin; Chuan Li; Yongbo Yang; Xuyang Liu; Dongmiao Wang; Jiehui Di
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

3.  Circular RNA circABCC4 as the ceRNA of miR-1182 facilitates prostate cancer progression by promoting FOXP4 expression.

Authors:  Changkun Huang; Huanghao Deng; Yinhuai Wang; Hongyi Jiang; Ran Xu; Xuan Zhu; Zhichao Huang; Xiaokun Zhao
Journal:  J Cell Mol Med       Date:  2019-07-03       Impact factor: 5.310

Review 4.  Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.

Authors:  Ju-Ha Kim; Jisung Hwang; Ji Hoon Jung; Hyo-Jung Lee; Dae Young Lee; Sung-Hoon Kim
Journal:  Mol Cancer       Date:  2019-12-09       Impact factor: 27.401

5.  FOXP4 inhibits squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway.

Authors:  Takeo Matsumoto; Takashi Iizuka; Mitsuhiro Nakamura; Takuma Suzuki; Megumi Yamamoto; Masanori Ono; Kyosuke Kagami; Haruki Kasama; Kousho Wakae; Masamichi Muramatsu; Shin-Ichi Horike; Satoru Kyo; Yasuhiko Yamamoto; Yasunari Mizumoto; Takiko Daikoku; Hiroshi Fujiwara
Journal:  Cancer Sci       Date:  2022-08-01       Impact factor: 6.518

Review 6.  The Dominant Role of Forkhead Box Proteins in Cancer.

Authors:  Duc-Hiep Bach; Nguyen Phuoc Long; Thi-Thu-Trang Luu; Nguyen Hoang Anh; Sung Won Kwon; Sang Kook Lee
Journal:  Int J Mol Sci       Date:  2018-10-22       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.